Turn Therapeutics Inc. appointed Robert R. Redfield, M.D., as Chief Scientific Officer on September 9, 2026. Dr. Redfield brings over four decades of experience in immunology and public health, including service as the former Director of the U.S. Centers for Disease Control and Prevention. In this role, he will contribute to the scientific strategy for lead candidate GX-03 across indications such as atopic dermatitis, onychomycosis, and hidradenitis suppurativa. Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases.
